+Vote!
Fiercebiotech (Free subscription) | 04/09/2008
Bayer Schering Pharma is handing back the worldwide commercialization rights to Epix's Vasovist , an MRA agent that has yet to win FDA approval. Their deal ends on March 1, 2009 and Bayer Schering will continue to supply Vasovist to the 19 countries where it is marketed. The FDA had rejected Vasovist, saying that it needed additional testing. Epix resubmitted its NDA earlier this year. "We are pleased...
+Vote!
Seeking Alpha (Free subscription) | 03/09/2008
Mark Barath submits: In a post on August 8 th , I advocated purchasing Schering Plough (SGP) and I spelled out my reasoning. In that post, I explained investor concerns of Vytorin. At that time, the ENHANCE panel found that Vytorin, a combination of Merck’s (MRK) Zocor and Schering’s Zetia, worked no better than Zocor alone at removing plaque from arteries. This information had the effect of reducing...
+Vote!
Medical,Health News and Articles (Free subscription) | 27/08/2008
Bayer Schering Pharma AG, Germany, will supply up to 110 million cycles of oral contraceptives yearly for family planning programs supported by the U.S. Agency for International Development (USAID) in developing countries worldwide. This will allow more than 8 million women per year to have access to modern and reliable hormonal contraception. The contract was [...]
+Vote!
World of stocks (Free subscription) | 14/08/2008
TheStreet.com Winners & Losers Financial Winners & Losers: Fannie Mae Tech Winners & Losers: Apple 8/13/2008 2:47 PM EDT Health Winners & Losers: Genentech 8/13/2008 4:59 PM EDT Schering Regroups After FDA Rejection 8/13/2008 4:49 PM EDT OPINION: U.S. Contracts in Iraq at What Cost? A new study by the Congressional Budget Office puts the spotlight on the billions of U.S. taxpayer dollars going to private...
+Vote!
The Street (Free subscription) | 13/08/2008
The company plans to rely on the sales of other drugs, particularly in overseas markets.
+Vote!
The Street (Free subscription) | 13/08/2008
A single patient's allergic reaction may have delayed U.S. approval by up to three years.
+Vote!
Market Wire (Free subscription) | 12/08/2008
LONDON, UNITED KINGDOM (MARKET WIRE) Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
+Vote!
Red Orbit (Free subscription) | 12/08/2008
By Anonymous United Kingdom - Bayer Schering Pharma AG and Genzyme Europe BV have informed physicians of six infectionrelated deaths, reported from a trial (CALGB10101) in which previously untreated, symptomatic B-cell chronic lymphocytic leukemia (CLL) patients were treated with fludarabine and rituximab followed by alemtuzumab for remission consolidation.
+Vote!
Down to Earth (Free subscription) | 05/08/2008
The Long Wait for Male Birth Control By Adam Goodman Just a few years ago, the new male contraceptive seemed like an inevitable reality. Major pharmaceutical companies like Wyeth, Schering and Organon were pumping millions into hormonal birth-control development programs for men, and researchers were breathlessly promising imminent production. more here
+Vote!
Forbes (Free subscription) | 01/08/2008
A barrage of worries about drug risks batter the stocks of several drug makers.
+Vote!
Miami Herald (Free subscription) | 01/08/2008
Government regulators dealt a major setback to Schering-Plough Corp., rejecting a highly anticipated drug designed to help patients recover from anesthesia.
+Vote!
Seattle Times (Free subscription) | 01/08/2008
Government regulators dealt a major setback to Schering-Plough Corp., rejecting a highly anticipated drug designed to help patients recover from anesthesia.
+Vote!
San Fransisco Chronicle (Free subscription) | 01/08/2008
Government regulators dealt a major setback to Schering-Plough Corp., rejecting a highly anticipated drug designed to help patients recover from anesthesia. The Food and Drug Administration notified the company Thursday that it will not approve its drug...
